# Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

> **NCT04279769** · PHASE1 · COMPLETED · sponsor: **Calithera Biosciences, Inc** · enrollment: 32 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** CB-280
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04279769
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-03
- **Primary completion:** 2021-11-23
- **Final completion:** 2021-11-23
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04279769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04279769, "Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04279769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*